104 related articles for article (PubMed ID: 36729084)
1. PATTERNS OF SUBRETINAL AND/OR INTRARETINAL FLUID RECURRENCE IN PATIENTS WHO RECEIVED AS-NEEDED RANIBIZUMAB THERAPY IN THE HARBOR TRIAL.
Adrean SD; Chaili S; Hill L; Amador-Patarroyo MJ
Retina; 2023 Apr; 43(4):624-631. PubMed ID: 36729084
[TBL] [Abstract][Full Text] [Related]
2. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.
Sadda S; Holekamp NM; Sarraf D; Ebraheem A; Fan W; Hill L; Blotner S; Spicer G; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Dec; 260(12):3781-3789. PubMed ID: 35687173
[TBL] [Abstract][Full Text] [Related]
3. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
4. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
Lally DR; Hill L; Amador-Patarroyo MJ
Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
[TBL] [Abstract][Full Text] [Related]
5. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
6. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
[TBL] [Abstract][Full Text] [Related]
7. Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis.
Zarbin M; Tsuboi M; Hill LF; Stoilov I
Ophthalmology; 2019 Jun; 126(6):849-855. PubMed ID: 30641096
[TBL] [Abstract][Full Text] [Related]
8. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
9. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
[TBL] [Abstract][Full Text] [Related]
10. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
[TBL] [Abstract][Full Text] [Related]
11. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
12. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
[TBL] [Abstract][Full Text] [Related]
13. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.
Waldstein SM; Philip AM; Leitner R; Simader C; Langs G; Gerendas BS; Schmidt-Erfurth U
JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463
[TBL] [Abstract][Full Text] [Related]
14. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
15. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.
Gianniou C; Dirani A; Jang L; Mantel I
Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
Zarbin MA; Hill L; Maunz A; Gliem M; Stoilov I
Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
[TBL] [Abstract][Full Text] [Related]
17. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
18. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.
Cuesta-Lasso M; Vieira-Barros A; Dolz-Marco R; Roig-Revert MJ; Badal J; Amselem L; Díaz-Llopis M; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2017 Mar; 92(3):101-106. PubMed ID: 27912913
[TBL] [Abstract][Full Text] [Related]
20. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.
Schmidt-Erfurth U; Vogl WD; Jampol LM; Bogunović H
Ophthalmology; 2020 Sep; 127(9):1211-1219. PubMed ID: 32327254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
